Journal of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Background
Alzheimer's
disease
(AD)
causes
cognitive
function
disorder
and
has
become
the
preeminent
cause
of
dementia.
Glucagon-like
peptide-1
(GLP-1)
receptor
agonists,
semaglutide,
have
shown
positive
effects
on
promoting
function.
However,
research
about
mechanism
semaglutide
as
a
therapeutic
intervention
in
AD
is
sparse.
Objective
This
study
was
to
investigate
efficacy
transgenic
mouse
model
pathology
explored
detailed
by
modulated
neuroinflammatory
processes.
Methods
Male
amyloid
precursor
protein/presenilin
1
(APP/PS1)
mice
were
treated
with
or
vehicle
for
8
weeks.
Morris
water
maze
test
used
assess
recognition
Pathology
analysis
performed
detect
deposition
plaques.
High-throughput
sequencing
applied
specify
mechanism.
Microglia
astrocyte
activation
assessed
immunofluorescent
staining.
Inflammation
cytokine
levels
evaluated
enzyme-linked
immunosorbent
assay
(ELISA).
Related
proteins
pathway
western
blot.
Results
Semaglutide
treatment
attenuated
Aβ
accumulation
enhanced
APP/PS1
mice.
Through
transcriptomic
profiling,
immunohistochemical
staining,
ELISA,
substantiated
inhibit
overactivation
microglia
astrocytes,
well
curtail
secretion
inflammatory
mediators.
Furthermore,
robustly
activated
AMP-activated
protein
kinase
(AMPK)
suppressed
toll-like
4
(TLR4)/nuclear
factor-kappa
B
(NF-κB)
signaling
cascade,
thus
reducing
dampening
cascade.
Conclusions
The
results
demonstrated
that
mitigated
neuroinflammation
decelerated
advance
Journal of Neuroinflammation,
Год журнала:
2025,
Номер
22(1)
Опубликована: Март 10, 2025
Abstract
Astrocytes
are
a
major
cell
type
in
the
central
nervous
system
(CNS)
that
play
key
role
regulating
homeostatic
functions,
responding
to
injuries,
and
maintaining
blood-brain
barrier.
also
regulate
neuronal
functions
survival
by
modulating
myelination
degradation
of
pathological
toxic
protein
aggregates.
have
recently
been
proposed
possess
both
autophagic
activity
active
phagocytic
capability
which
largely
depend
on
sufficiently
acidified
lysosomes
for
complete
cellular
cargos.
Defective
lysosomal
acidification
astrocytes
impairs
their
resulting
accumulation
debris,
excessive
myelin
lipids,
aggregates,
ultimately
contributes
propagation
neuroinflammation
neurodegenerative
pathology.
Restoration
impaired
represent
new
neuroprotective
strategy
therapeutic
direction.
In
this
review,
we
summarize
pathogenic
factors,
including
neuroinflammatory
signaling,
metabolic
stressors,
lipid
mediated
toxicity,
contribute
impairment
associated
dysfunction
astrocytes.
We
discuss
astrocyte-mediated
primarily
context
diseases
along
with
other
brain
injuries.
then
highlight
re-acidification
as
restore
well
degradative
capacity
conclude
providing
future
perspectives
phagocytes
crosstalk
CNS
cells
impart
or
effects.
Proceedings of the National Academy of Sciences,
Год журнала:
2025,
Номер
122(13)
Опубликована: Март 24, 2025
GWAS
have
identified
tyrosine
kinase
2
(TYK2)
variants
in
multiple
inflammatory
disorders,
specifically
a
protective
hypomorphic
TYK2
allele
(P1104A)
sclerosis
(MS).
Impaired
signaling
within
the
central
nervous
system
(CNS)
may
impart
effects
of
P1104A
MS.
We
deployed
brain-penetrant
inhibitors
(cTYK2i)
alongside
peripherally
restricted
inhibitor
(pTYK2i;
BMS-986165)
to
untangle
contributions
inhibition
diverse
models
neuroinflammation.
While
pTYK2i
had
little
impact,
cTYK2i
reduced
clinical
score,
lymphoid
cell
infiltration,
and
cytokines/chemokines
experimental
autoimmune
encephalomyelitis
(EAE).
Microglial
activation
was
attenuated
cTYK2i-treated
EAE
spinal
cords
circulating
neurofilament
light
(NfL)
plasma
cerebral
fluid
(CSF).
Additionally,
an
antibody-mediated
mouse
model
primary
progressive
MS
(PPMS).
Finally,
we
demonstrate
has
robust
impact
on
unique
subset
activated
astrocytes
termed
Interferon-Responsive-Reactive-Astrocytes
(IRRA).
The
data
presented
herein
identify
key
role
for
CNS
regulating
neuroinflammation
solidify
as
potential
therapeutic
target
Journal of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Background
Alzheimer's
disease
(AD)
causes
cognitive
function
disorder
and
has
become
the
preeminent
cause
of
dementia.
Glucagon-like
peptide-1
(GLP-1)
receptor
agonists,
semaglutide,
have
shown
positive
effects
on
promoting
function.
However,
research
about
mechanism
semaglutide
as
a
therapeutic
intervention
in
AD
is
sparse.
Objective
This
study
was
to
investigate
efficacy
transgenic
mouse
model
pathology
explored
detailed
by
modulated
neuroinflammatory
processes.
Methods
Male
amyloid
precursor
protein/presenilin
1
(APP/PS1)
mice
were
treated
with
or
vehicle
for
8
weeks.
Morris
water
maze
test
used
assess
recognition
Pathology
analysis
performed
detect
deposition
plaques.
High-throughput
sequencing
applied
specify
mechanism.
Microglia
astrocyte
activation
assessed
immunofluorescent
staining.
Inflammation
cytokine
levels
evaluated
enzyme-linked
immunosorbent
assay
(ELISA).
Related
proteins
pathway
western
blot.
Results
Semaglutide
treatment
attenuated
Aβ
accumulation
enhanced
APP/PS1
mice.
Through
transcriptomic
profiling,
immunohistochemical
staining,
ELISA,
substantiated
inhibit
overactivation
microglia
astrocytes,
well
curtail
secretion
inflammatory
mediators.
Furthermore,
robustly
activated
AMP-activated
protein
kinase
(AMPK)
suppressed
toll-like
4
(TLR4)/nuclear
factor-kappa
B
(NF-κB)
signaling
cascade,
thus
reducing
dampening
cascade.
Conclusions
The
results
demonstrated
that
mitigated
neuroinflammation
decelerated
advance